Monodoses / Single-Doses are approved by numerous regulatory environmental point of view, Does your Rommelag CMO bodies such as EMA (Europe), FDA (USA), do you discuss your technolo-entity work for the pharmaceu- ANVISA (Brazil) or other official inspection gy’s future? tical industry? bodies. Our customers trust, that our filling systems comply to GMP regulations at any A.H: In medicine, plastic is established A.H: Yes, our CMO division is working time. as a versatile raw material that can save for numerous players in the pharmaceutical What are your current ways of lives in emergency situations. Blood bags area. Our benefit is, that we do not own and infusion bottles are one of the most or develop products/ recipes. We are able improving on this technology? common examples that illustrate the to provide filling processes for even tiny importance of plastic in medicine. It can quantities (from as little as 1 l right through A.H: We strive for a long-lasting be bought cheaply and is therefore sui- to huge amounts in cubic volumes), labora- partnership with our customers. This also table as a practical disposable product. It tory runs, scale-ups, test runs, and stability, includes developing individual packaging is therefore ideal for preventing the risk registration, clinical, and market batches. designs in cooperation with our customers, of spreading germs. We as Rommelag With over 100 individual, freely available testing new materials and material compo- believe, that our products make the world moulds with different filling volumes form sitions and offering test fillings. better, day after day, by providing access 0,2ml up to 1l, we have the flexibility to to basic live saving drugs, even in remote quickly respond to market needs. Using plastic, a material destinations. Presently there are develop- ments to use environmental friendly plas- Interview made by Rachelle Lemoine increasingly criticized from an tic materials. 88 The Pharmaceutical Post 01 / Janvier - 2020